for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alexion Pharmaceuticals, Inc.

ALXN.O

Latest Trade

114.13USD

Change

0.00(-0.00%)

Volume

2,750,356

Today's Range

112.72

 - 

115.25

52 Week Range

72.67

 - 

121.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
114.13
Open
114.97
Volume
2,750,356
3M AVG Volume
39.09
Today's High
115.25
Today's Low
112.72
52 Week High
121.50
52 Week Low
72.67
Shares Out (MIL)
219.17
Market Cap (MIL)
25,332.01
Forward P/E
10.54
Dividend (Yield %)
--

Next Event

Alexion Pharmaceuticals Inc Investor Day (Virtual)

Latest Developments

More

Alexion Reports Q2 Non-Gaap Earnings Per Share $3.11

ImmunoGen Appoints Susan Altschuller As CFO

Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Industry

Major Drugs

Contact Info

121 Seaport Blvd

BOSTON, MA

02210-2050

United States

+1.475.2302596

https://alexion.com/

Executive Leadership

David R. Brennan

Independent Chairman of the Board

Ludwig N. Hantson

Chief Executive Officer, Director

Aradhana Sarin

Executive Vice President, Chief Financial Officer

Indrani Franchini

Executive Vice President, Chief Compliance Officer

Ellen Chiniara

Executive Vice President, Chief Legal Officer. Corporate Secretary

Key Stats

2.17 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

3.6K

2018

4.1K

2019

5.0K

2020(E)

5.7K
EPS (USD)

2017

5.860

2018

7.920

2019

10.530

2020(E)

10.996
Price To Earnings (TTM)
30.97
Price To Sales (TTM)
4.58
Price To Book (MRQ)
2.41
Price To Cash Flow (TTM)
20.97
Total Debt To Equity (MRQ)
23.24
LT Debt To Equity (MRQ)
22.03
Return on Investment (TTM)
5.81
Return on Equity (TTM)
5.41

Latest News

Latest News

Roche gets U.S. approval for Enspryng, takes on Alexion's Soliris

The U.S. Food and Drug Administration on Saturday approved Roche's Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion's Soliris in a costly treatment area.

Alexion to pay $21.5 million to settle SEC foreign bribery probe

Alexion Pharmaceuticals Inc will pay nearly $21.5 million to resolve claims it improperly paid Turkish and Russian officials to secure favorable treatment for its main drug, Soliris, the U.S. Securities and Exchange Commission said Thursday.

Alexion pays $21 million resolving charges of breaking U.S. foreign corruption law: SEC

Alexion Pharmaceuticals <ALXN.O> has agreed to pay $21 million to resolve U.S. charges that it violated a major anti-corruption law when two of its subsidiaries paid Turkish and Russian officials for favorable treatment of its Soliris drug, the top securities regulator said...

BRIEF-Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission

* ALEXION PHARMACEUTICALS-ULTOMIRIS GETS MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS,CHILDREN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Alexion Announces Phase 3 Study Of Weekly Subcutaneous Ultomiris Met Primary Endpoint

* ALEXION ANNOUNCES PHASE 3 STUDY OF WEEKLY SUBCUTANEOUS ULTOMIRIS® (RAVULIZUMAB-CWVZ) MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Activist investor Elliott pushes Alexion Pharma to sell itself

Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.

Elliott again pushes Alexion Pharma to explore a sale

Activist investor Elliott Management on Tuesday revived its call for a sale of Alexion Pharmaceuticals Inc, months after the company rejected the hedge fund's earlier demand.

BRIEF-Elliott Advisors Sends Letter To Alexion Pharmaceuticals

* ELLIOTT ADVISORS, IN LETTER TO ALEXION, SAYS BEST APPROACH FOR ALEXION IS IMMEDIATE EXPLORATION OF A SALE

BRIEF-Alexion Pharmaceuticals Sees FY Revenue $5,230 Mln To $5,330 Mln

* Q1 REVENUE $1.445 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.36 BILLION

BRIEF-Portola Pharmaceuticals Cancels Q1 Results Webcast And Conference Call Following Agreement To Be Acquired By Alexion

* PORTOLA PHARMACEUTICALS CANCELS FIRST QUARTER 2020 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL FOLLOWING AGREEMENT TO BE ACQUIRED BY ALEXION Source text for Eikon: Further company coverage:

Alexion bets on Portola's bleeding antidote with $1.41 billion deal

Alexion Pharmaceuticals Inc <ALXN.O> on Tuesday agreed to buy Portola Pharmaceuticals Inc <PTLA.O> in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.

CORRECTED-UPDATE 1-Alexion to buy Portola Pharmaceuticals in $1.41 bln deal

Drugmaker Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a deal that values its smaller rival at $1.41 billion to gain access to a treatment for reversing the effects of blood thinners.

Alexion to buy Portola Pharmaceuticals in $1.41 bln deal

Alexion Pharmaceuticals Inc. on Tuesday agreed to buy Portola Pharmaceuticals Inc in a deal that values the U.S. drug developer at $1.41 billion.

BRIEF-Alexion To Acquire Portola

* ALEXION PHARMACEUTICALS INC - DEAL FOR $18 PER SHARE IN CASH

Alexion to study rare blood-disorder drug in severe COVID-19 patients

Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome.

Alexion to study rare blood-disorder drug in severe COVID-19 patients

Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome.

BRIEF-Alexion Announces Plans To Initiate Phase 3 Study Of Ultomiris® In Hospitalized Patients With Severe Covid-19

* ALEXION ANNOUNCES PLANS TO INITIATE PHASE 3 STUDY OF ULTOMIRIS® (RAVULIZUMAB-CWVZ) IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's FY 2019 Total Compensation Was $18.9 Mln vs $16.5 Mln In FY 2018 - SEC Filing

* ALEXION PHARMACEUTICALS INC SAYS CEO LUDWIG HANTSON'S FY 2019 TOTAL COMPENSATION WAS $18.9 MILLION VERSUS $16.5 MILLION IN FY 2018 - SEC FILING

BRIEF-Alexion Announces Upcoming Data Presentations At Annual Meeting Of The American Academy Of Neurology

* ALEXION ANNOUNCES UPCOMING DATA PRESENTATIONS AT 72ND ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up